KalVista Pharmaceuticals, Inc.
KALV
$14.66
$1.148.43%
NASDAQ
| 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -160.83M | -160.83M | -141.18M | -133.60M | -114.12M |
| Total Depreciation and Amortization | 742.00K | 742.00K | 714.00K | 672.00K | 650.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.11M | 20.11M | 12.38M | 25.03M | 17.31M |
| Change in Net Operating Assets | 12.43M | 12.43M | 14.82M | 19.89M | 13.27M |
| Cash from Operations | -127.55M | -167.19M | -152.91M | -127.65M | -122.54M |
| Capital Expenditure | -595.00K | -595.00K | -326.00K | -60.00K | -55.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.05M | 27.05M | 42.68M | -80.45M | -95.67M |
| Cash from Investing | 26.45M | 75.12M | 91.02M | -31.83M | -47.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 59.68M | 59.68M | 61.39M | 156.52M | 100.26M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 119.96M | 119.96M | 98.04M | 148.35M | 53.12M |
| Cash from Financing | 179.64M | 179.94M | 159.73M | 305.17M | 153.68M |
| Foreign Exchange rate Adjustments | 4.84M | 4.84M | 2.23M | -1.21M | -578.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.38M | 93.12M | 100.48M | 144.89M | -16.09M |